Overview

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Status:
Active, not recruiting

Trial end date:
2026-05-31

Target enrollment:

Participant gender:

Summary

Parts A & B: Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to Advagraf® immunosuppression to compare exposure and one year follow-up for safety and efficacy. Part C: Continuation of long-term follow-up and provision of ongoing study medication to subjects to whom Advagraf® is currently not available.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Europe Ltd.

Treatments:

Tacrolimus